Advarra is pleased to announce the acquisition of IntegReview IRB. The addition of IntegReview enables Advarra to continue its expansion of comprehensive review solutions capabilities in North America.
“IntegReview and Advarra share a mission-driven passion for protecting clinical trial participants,” said Gadi Saarony, CEO of Advarra. “Our aim is to benefit clinical trials and drug development through expanded subject matter expertise, technology-enabled efficiencies, and continuing commitment to ethics, quality, and service. We are excited to welcome more talent to enhance our combined capabilities and geographic footprint.”
The Austin, Tex. headquarters for IntegReview will become the first Advarra office in the southern US. The acquisition also increases depth of expertise in many key areas, most notably in early phase research.
“We are excited to be a part of the Advarra family” said Lynn Meyer, founder and Managing Partner of IntegReview. “We were attracted to Advarra’s extensive regulatory depth and their model of integrated IRB operations and focus on building client relationships and deep collaboration with the site community.”
For more information, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.